Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis

被引:0
|
作者
Sato E. [1 ]
Kamijo-Ikemori A. [2 ,4 ]
Oikawa T. [3 ]
Okuda A. [3 ]
Sugaya T. [3 ,4 ]
Kimura K. [5 ]
Nakamura T. [1 ,4 ]
Shibagaki Y. [4 ]
机构
[1] Division of Nephrology, Department of Medicine, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo,Chiba
[2] Department of Anatomy, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki,Kanagawa
[3] Cmic Holdings Co. Ltd., Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo
[4] Department of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki, 216-8511, Kanagawa
[5] Department of Internal Medicine, Japan Community Health Care Organization, Tokyo Takanawa Hospital, Tokyo
关键词
AKI; Biomarker; L-FABP; Oxidative stress; POC; Sepsis;
D O I
10.1186/s41100-017-0107-x
中图分类号
学科分类号
摘要
Sepsis due to microbial invasion often causes multiple organ failure (MOF), including acute kidney injury (AKI), with high mortality rates in serious cases. Hence, there is an urgent need for diagnostic biomarkers that can be used to rapidly, accurately, and easily detect sepsis to identify the condition early and guide the selection of appropriate treatment. Liver-type fatty acid-binding protein (L-FABP), which localizes in renal proximal tubules, is excreted into the urine in response to oxidative stress-induced tubular injury. Because of this mechanism, L-FABP has been reported to be a useful urinary biomarker not only for renal disease but also for the severity of sepsis. Based on this concept, we developed a new L-FABP point-of-care (POC) assay kit that can be used to rapidly measure human L-FABP in the urine to further improve the usefulness of this biomarker in clinical settings. In this review, we describe the molecular mechanisms of L-FABP, its clinical usefulness, and the performance of the POC assay kit. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [21] URINARY LIVER-TYPE FATTY ACID-BINDING PROTEIN IN SEPTIC SHOCK: EFFECT OF POLYMYXIN B-IMMOBILIZED FIBER HEMOPERFUSION
    Nakamura, Tsukasa
    Sugaya, Takeshi
    Koide, Hikaru
    SHOCK, 2009, 31 (05): : 454 - 459
  • [22] Tissue expression and urinary excretion of liver-type fatty acid binding protein in older dogs with or without early signs of chronic kidney disease
    Marynissen, Sofie
    Demeyere, Kristel
    Daminet, Sylvie
    Meyer, Evelyne
    Chiers, Koen
    Paepe, Dominique
    VETERINARY PATHOLOGY, 2025,
  • [23] Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats
    Tanabe, Jun
    Ogura, Yuji
    Kosaki, Keisei
    Nagai, Yoshio
    Sugaya, Takeshi
    Ohata, Keiichi
    Watanabe, Shiika
    Ichikawa, Daisuke
    Inoue, Kazuho
    Hoshino, Seiko
    Kimura, Kenjiro
    Maeda, Seiji
    Shibagaki, Yugo
    Kamijo-Ikemori, Atsuko
    JOURNAL OF DIABETES RESEARCH, 2020, 2020
  • [24] Decreased Expression of Liver-Type Fatty Acid-Binding Protein is Associated with poor Prognosis in Hepatocelluar Carcinoma
    Wang, Bin
    Tao, Xuan
    Huang, Chuan-Zhong
    Liu, Jing-Feng
    Ye, Yun-Bin
    Huang, Ai-Min
    HEPATO-GASTROENTEROLOGY, 2014, 61 (133) : 1321 - 1326
  • [25] Elevation of Urinary Liver-Type Fatty Acid-Binding Protein Is a Harbinger of Poor Patient Prognosis after Allogeneic Stem Cell Transplantation
    Shingai, Naoki
    Ota, Akihito
    Kato, Kana
    Kondo, Kaori
    Sadaga, Yasutaka
    Kato, Chika
    Sakai, Satoshi
    Kambara, Yasuhiro
    Nabe, Yoshimi
    Asano, Kazuya
    Teshima, Koh
    Kurihara, Kazuya
    Ouchi, Fumihiko
    Fujiwara, Hiroki
    Shimabukuro, Masashi
    Inai, Kazuki
    Jinguji, Atsushi
    Toya, Takashi
    Shimizu, Hiroaki
    Najima, Yuho
    Kobayashi, Takeshi
    Sugaya, Takeshi
    Ando, Minoru
    Doki, Noriko
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 121e1 - 121e8
  • [26] Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease
    Atsuko Kamijo
    Takeshi Sugaya
    Akihisa Hikawa
    Masaya Yamanouchi
    Yasunobu Hirata
    Toshihiko Ishimitsu
    Atsushi Numabe
    Masao Takagi
    Hiroshi Hayakawa
    Fumiko Tabei
    Tokuichiro Sugimoto
    Naofumi Mise
    Masao Omata
    Kenjiro Kimura
    Molecular and Cellular Biochemistry, 2006, 284 : 175 - 182
  • [27] Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease
    Kamijo, Atsuko
    Sugaya, Takeshi
    Hikawa, Akihisa
    Yamanouchi, Masaya
    Hirata, Yasunobu
    Ishimitsu, Toshihiko
    Numabe, Atsushi
    Takagi, Masao
    Hayakawa, Hiroshi
    Tabei, Fumiko
    Sugimoto, Tokuichiro
    Mise, Naofumi
    Omata, Masao
    Kimura, Kenjiro
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2006, 284 (1-2) : 175 - 182
  • [28] Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Worsening Renal Function in Patients With Acute Heart Failure
    Okubo, Yousaku
    Sairaku, Akinori
    Morishima, Nobuyuki
    Ogi, Hiroshi
    Matsumoto, Takeshi
    Kinoshita, Hiroki
    Kihara, Yasuki
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : 520 - 524
  • [29] Diagnostic implications of urinary liver-type fatty acid-binding protein and 8-hydroxy-2′-deoxyguanosine in forensic autopsy cases
    Kashiwagi, Masayuki
    Sugimura, Tomoko
    Matsusue, Aya
    Hara, Kenji
    Waters, Brian
    Kubo, Shin-ichi
    LEGAL MEDICINE, 2013, 15 (03) : 140 - 144
  • [30] Significance of urinary liver-type fatty acid-binding protein in patients with normal renal function after undergoing intestinal urinary diversion: a preliminary study
    Maehana, Takeshi
    Ichihara, Koji
    Takahashi, Satoshi
    Takahashi, Yusuke
    Hashimoto, Kohei
    Tanaka, Toshiaki
    Masumori, Naoya
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (10) : 1151 - 1157